High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

Cited by (285)

Items 101–200 of 285

1. In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts
   Susanne Lütje, Gerben M. Franssen, Ken Herrmann, Otto C. Boerman, Mark Rijpkema, Martin Gotthardt, Sandra Heskamp · 2019 · Journal of Nuclear Medicine
2. Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [ 177 Lu]Lu-PSMA-617
   Sebastian Martin, Roswitha Tönnesmann, Ina Hierlmeier, Stephan Maus, Florian Rosar, Juri Ruf, Jason P. Holland, Samer Ezziddin, Mark Daniel Bartholomä · 2021 · Journal of Medicinal Chemistry
3. Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives
   Paweł Kiełb, Kamil Kowalczyk, Adam Gurwin, Łukasz Nowak, Wojciech R. Krajewski, Roman Sosnowski, Tomasz Szydełko, Bartosz Małkiewicz · 2023 · Biomedicines
4. Advances in Urologic Imaging
   Michael S. Hofman, Amir Iravani, Tatenda Calvin Nzenza, Declan G. Murphy · 2018 · Urologic Clinics of North America
5. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy
   Anna Gasińska, Janusz Jaszczyński, Urszula Rychlik, Elżbieta Łuczyńska, M. Pogodziński, Palaczynski Mikolaj · 2019 · Pathology & Oncology Research
6. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers
   Laura Stumm, Lia Burkhardt, Stefan A. Steurer, Ronald Simon, Meike Adam, Andreas Becker, Guido Sauter, Sarah Jane Pauline Minner, Thorsten Schlomm, Hüseyin Sirma et al. · 2013 · Journal of Clinical Pathology
7. Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
   Susanne Lütje, Sebastian Blex, Benedikt Gomez, Benedikt M. Schaarschmidt, Lale Umutlu, Michael Forsting, Walter Jentzen, Andreas Bockisch, Thorsten Dirk Poeppel, Axel Wetter · 2016 · PLoS ONE
8. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
   Shiming Zang, Guoqiang Shao, Can Cui, Tiannv Li, Yue Huang, Xiaochen Yao, Qiu Fan, Zejun Chen, Jin Du, Ruipeng Jia et al. · 2017 · Oncotarget
9. PSMA-targeted therapy for non-prostate cancers
   Jarey H. Wang, Ana P. Kiess · 2023 · Frontiers in Oncology
10. New aspects of molecular imaging in prostate cancer
    Francesco Ceci, Paolo Castellucci, Juliano J. Cerci, Stefano Fanti · 2017 · Methods
11. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology
    Arveen A. Kalapara, Zita E. Ballok, Shakher Ramdave, Richard O’Sullivan, Andrew Ryan, Badrinath R. Konety, Jeremy Grummet, Mark Frydenberg · 2021 · European Urology Oncology
12. Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Ke Gao, Wenjin Xi, Jianxin Ni, Jun Jiang, Yonghua Lei, Li Li, Jie Chu, Ruixiao Li, Yongpan An, Yanan Ouyang et al. · 2024 · Biomaterials
13. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer
    Francesco Ceci, Paolo Castellucci, Stefano Fanti · 2019 · The Quarterly Journal of Nuclear Medicine and Molecular Imaging
14. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer
    Christoph M. Burdelski, Tatsiana Dieckmann, Asmus Heumann, Claudia Hube‐Magg, Martina Kluth, Burkhard Beyer, Thomas P Steuber, Raisa S. Pompe, Markus Graefen, Ronald Simon et al. · 2016 · Tumor Biology
15. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy
    Katharina Grupp, M Habermann, Hüseyin Sirma, Ronald Simon, Stefan A. Steurer, Claudia Hube‐Magg, Kristina Prien, Lia Burkhardt, Karolina Jedrzejewska, Georg Salomon et al. · 2013 · Modern Pathology
16. Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis
    Hüseyin Sirma, MARGARETHE BROEMEL, Laura Stumm, TINA TSOURLAKIS, Stefan A. Steurer, Pierre Tennstedt, Georg Salomon, Uwe H.G. Michl, Alexander Haese, Ronald Simon et al. · 2013 · Oncology Letters
17. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
    Kurt D. Bernacki, Kristina L. Fields, Michael H. Roh · 2013 · Diagnostic Cytopathology
18. Integrated 68Ga-HBED-CC-PSMAPET/MRI in patients with suspected recurrent prostate cancer
    Joseph Cohnen, Benedikt Gomez, J Grüneisen, Lino Morris Sawicki, Herbert Rubben, Andreas Bockisch, Lale Umutlu, Thorsten Dirk Pöppel, Axel Wetter, Susanne Lütje · 2017 · Nuklearmedizin - NuclearMedicine
19. Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer
    Zhonglin Cai, Haidi Lv, Wenjuan Cao, Chuan Zhou, Qiangzhao Liu, Hui Li, Fenghai Zhou · 2017 · Molecular Medicine Reports
20. PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness
    Mengxia Chen, Xuefeng Qiu, Qing Hua Zhang, Chengwei Zhang, Yi-Hua ZHOU, Xiaozhi Zhao, Yao Shi Fu, Feng Wang, Hongqian Guo · 2022 · The Quarterly Journal of Nuclear Medicine and Molecular Imaging
21. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
    Ann-Christin Eder, Martin K.-H. Schäfer, Jana Schmidt, Ulrike Bauder‐Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka, Matthias Eder · 2021 · Journal of Nuclear Medicine
22. Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
    Konstantin Egon Seifert, Robert Seifert, Katharina Kessel, Wolfgang Roll, Katrin Schlack, Martin Boegemann, Kambiz Rahbar · 2021 · Cancers
23. BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)
    Mohsen Beheshti, Thomas Kunit, Silke Haim, Seyed Rasoul Zakavi, Christian Schiller, Andrew Wills Stephens, Ludger M. Dinkelborg, Werner Langsteger, Wolfgang C. Loidl · 2014 · Molecular Imaging and Biology
24. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence
    Alexandra Pust, Dominik Kylies, Claudia Hube‐Magg, Martina Kluth, Sarah Jane Pauline Minner, Christina Koop, Tobias J. Grob, Markus Graefen, Georg Salomon, Maria Christina Tsourlakis et al. · 2015 · Human Pathology
25. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial
    Samantha G. Koschel, Kim Taubman, Thomas Sutherland, Kelvin Yap, Michael Chao, Mario Guerrieri, Angela Benson, Michelle Starmans, Graeme Byrne, Grace Ong et al. · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
26. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
    Andrew J. Armstrong, Oliver A. Sartor, Johann Sebastian De Bono, Kim Chi, Karim S. Fizazi, Bernd Joachim Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad C et al. · 2024 · European Urology
27. System-level optimization in spectroscopic photoacoustic imaging of prostate cancer
    Yixuan Wu, Jeeun Kang, Wojciech G. Lesniak, Ala Lisok, Haichong K. Zhang, Russell H. Taylor, Martin G. Pomper, Emad M. Boctor · 2022 · Photoacoustics
28. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
    Loïc Djaileb, Wesley Robert Armstrong, Daniel Thompson, Andrei Gafita, Andrea Farolfi, Abhejit Rajagopal, Tristan Grogan, Kathleen Nguyen, Matthias Benz, Masatoshi Hotta et al. · 2023 · European Urology
29. A VISION Substudy of Reader Agreement on ⁶⁸ Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy
    Kuo, Phillip H., Yoo, Don C., Avery, Ryan, Seltzer, Marc, Calais, Jeremie, Nagarajah, James, Weber, Wolfgang A., Fendler, Wolfgang P., Hofman, Michael S., Krause, Bernd J. et al. · 2023 · Journal of Nuclear Medicine
30. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
    Ivana Bratić Hench, Richard L. Cathomas, Luigi Costa, Natalie Fischer, Silke Gillessen, Jürgen Hench, Thomas Hermanns, Eloïse A. Kremer, Walter B. Mingrone, Ricardo Pereira Mestre et al. · 2019 · Cancers
31. Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial
    Giacomo Feliciani, Monica Celli, Fabio Ferroni, Enrico Menghi, Irene Azzali, Paola Caroli, Federica Matteucci, Domenico Barone, Giovanni Paganelli, Anna Sarnelli · 2022 · Cancers
32. High‐Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer
    Christoph M. Burdelski, Rami Shihada, Andrea Hinsch, Alexander Angerer, Cosima Göbel, Emily Friedrich, Claudia Hube‐Magg, Susanne Burdak‐Rothkamm, Martina Kluth, Ronald Simon et al. · 2017 · The Prostate
33. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row
    Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Høyer, Barbara Alicja Jereczek‐Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Gisella Di Muzio et al. · 2018 · World Journal of Urology
34. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer
    Luca Filippi, Viviana Frantellizzi, Agostino Chiaravalloti, Mariano Pontico, Maria Silvia De Feo, Ferdinando Corica, Melissa Montebello, Orazio Schillaci, Giuseppe De Vincentis, Oreste Bagni · 2021 · International Journal of Molecular Sciences
35. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer
    Sergio Muñoz Vázquez, Heike Endepols, Thomas H. Fischer, Samir Tawadros, Melanie Hohberg, Beate Zimmermanns, Felix Dietlein, Bernd Neumaier, Alexander E. Drzezga, Markus Dietlein et al. · 2021 · Molecular Imaging and Biology
36. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
    He-Ying Duan, P. Ghanouni, B. Daniel, J. Rosenberg, A. Thong, Christian A. Kunder, C. Aparici, G. Davidzon, F. Moradi, G. Sonn et al. · 2022 · Journal of Nuclear Medicine
37. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers
    Christoph M. Burdelski, Michael Fitzner, Claudia Hube‐Magg, Martina Kluth, Asmus Heumann, Ronald Simon, Till Krech, Till Sebastian Clauditz, Franziska Büscheck, Stefan A. Steurer et al. · 2017 · Neoplasia
38. Functional Imaging for Prostate Cancer: Therapeutic Implications
    Carina Marí Aparici, Youngho Seo · 2012 · Seminars in Nuclear Medicine
39. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm
    Hebert Alberto Vargas, Jan Grimm, Olivio F. Donati, Evis Sala, Hedvig Hricak · 2015 · European Radiology
40. Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
    Katharina Kessel, Christof Bernemann, Martin Bögemann, Kambiz Rahbar · 2021 · Cancers
41. Antibody-drug conjugates targeting prostate-specific membrane antigen
    William C. Olson · 2014 · Frontiers in bioscience
42. Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging
    Dongzhi Yang, Anthony B. Comeau, Wayne D. Bowen, Robert H. Mach, Brian Dale Ross, Hao Hong, Marcian E. Van Dort · 2017 · Molecular Pharmaceutics
43. Targetable clinical nanoparticles for precision cancer therapy based on disease-specific molecular inflection points
    Kaittanis, Charalambos, Bolaender, Alexander, Yoo, Barney, Shah, Nilesh, Ouerfelli, Ouathek, Grimm, Jan · 2017 · Nano Letters
44. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer
    Andreas Holger Marx, Lena Koopmann, Doris Höflmayer, Franziska Büscheck, Claudia Hube‐Magg, Stefan A. Steurer, Till Eichenauer, Till Sebastian Clauditz, Waldemar Wilczak, Ronald Simon et al. · 2021 · Cancer Biology and Medicine
45. Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment
    Lital Cohen, Yehuda G. Assaraf, Yoav D. Livney · 2021 · Pharmaceutics
46. SERS-Based Quantification of PSMA in Tissue Microarrays Allows Effective Stratification of Patients with Prostate Cancer
    Manjari Bhamidipati, Geuntaek Lee, Isaac Kim, Laura Fabris · 2018 · ACS Omega
47. Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer
    C. Unger, Peter Bronsert, Kerstin Michalski, Anna Bicker, Ingolf Juhasz-Böss · 2022 · Geburtshilfe und Frauenheilkunde
48. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties
    Young‐Do Kwon, Jun Young Lee, Minh Thanh La, Sun Joo Lee, Sun Hwa Lee, Jeong Hoon Park, Hee‐Kwon Kim · 2020 · European Journal of Medicinal Chemistry
49. Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues
    Tamara Sequeiros, Marta García, Melania Montes, Mireia Oliván, Marina Rigau, Eva Colás, Inés M. de Torres, Juan Moróte, Jaume Reventós, Andreas Doll · 2013 · BioMed Research International
50. The efficiency of 18 F labelling of a prostate specific membrane antigen ligand via strain-promoted azide–alkyne reaction: reaction speed versus hydrophilicity
    Mengzhe Wang, Christopher D. McNitt, Hui Wang, Xiaofen Ma, Sarah M. Scarry, Zhanhong Wu, Vladimir V. Popik, Zibo Li · 2018 · Chemical Communications
51. 68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?
    Snir Dekalo, Jonathan Kuten, Nicola J. Mabjeesh, Avi Beri, Einat Even‐Sapir, Ofer Yossepowitch · 2019 · Urologic Oncology Seminars and Original Investigations
52. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer
    Samantha G. Koschel, Declan G. Murphy, Michael S. Hofman, Lih‐Ming Wong · 2019 · Current Opinion in Urology
53. Salvage Radiotherapy for Prostate Cancer
    Kato Rans, Charlien Berghen, Steven Joniau, Gert De Meerleer · 2020 · Clinical Oncology
54. In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
    Jinghang Xie, Meghan A. Rice, Zixin Chen, Yunfeng Cheng, En‐Chi Hsu, Min Chen, Guosheng Song, Liyang Cui, Kaixiang Zhou, Jessa B. Castillo et al. · 2021 · Cancer Research
55. Upregulation of SPDEF is associated with poor prognosis in prostate cancer
    Jan Meiners, Katharina Schulz, Katharina M�ller, Doris H�flmayer, Christoph M. Burdelski, Claudia Hube‐Magg, Ronald Simon, Cosima G�bel, Andrea Hinsch, Viktor Reiswich et al. · 2019 · Oncology Letters
56. Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
    Hui Wang, Marianne Remke, Thomas D Horn, Kristina Schwamborn, Yiyao Chen, Katja Steiger, Wilko Weichert, Hans‐Jürgen Wester, Margret Schottelius, Wolfgang Weber et al. · 2023 · EJNMMI Research
57. In-Memory Sensing and Computing for Cancer Diagnostics: A Perspective Paper
    Sandro Carrara, Junrui Chen, Kapil Bhardwaj, Ata Jedari Golparvar, Gian Luca Barbruni · 2023 · IEEE Transactions on Biomedical Circuits and Systems
58. Current status of PSMA-targeted imaging and therapy
    Hui Wang, GuanNan Li, Jie Zhao, Matthias J. Eiber, Rong Tian · 2024 · Frontiers in Oncology
59. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
    Katharina Grupp, Thorsten Simon Höhne, Kristina Prien, Claudia Hube‐Magg, Maria Christina Tsourlakis, Hüseyin Sirma, Taher Pham, Hans Heinzer A, Markus Graefen, Uwe H.G. Michl et al. · 2013 · Experimental and Molecular Pathology
60. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy
    Cem Önal, Neşe Torun, Ezgi Oymak, Ozan Cem Güler, Mehmet Reyhan, Ali Fuat Yapar · 2020 · Annals of Nuclear Medicine
61. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
    Simon Kind, Franziska Büscheck, Doris Höflmayer, Claudia Hube‐Magg, Martina Kluth, Maria Christina Tsourlakis, Stefan A. Steurer, Till Sebastian Clauditz, Andreas M. Luebke, Eike Burandt et al. · 2019 · World Journal of Urology
62. PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer
    Xiao-Lei Meng, Xiaolin Hu, Shan Gao, Wenrui Jia, Sai Zhang, Siqi Zhang, Xiao Wang, Shumin Ma, Chong Qin · 2025 · Journal of Medicinal Chemistry
63. Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands
    Nathalie Heynickx, Charlotte Segers, Amelie Coolkens, Sarah Baatout, Koen Vermeulen · 2023 · Pharmaceuticals
64. 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone
    Jinhui Yang, Jian Li, Ling Xiao, Ming Zhou, Zhihui Fang, Yi Cai, Yongxiang Tang, Shuo Hu · 2023 · Cancer Imaging
65. Molecular MR Imaging of Prostate Cancer
    Avan Kader, Julia Brangsch, Jan Ole Kaufmann, Jing Zhao, Dilyana Branimirova Mangarova, Jana Möckel, Lisa C. Adams, Ingolf Sack, Matthias Taupitz, Bernd Hamm et al. · 2020 · Biomedicines
66. Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis
    David C. Chen, Siyu Huang, Nathan P. Papa, Shankar Siva, Damien Michael Bolton, Nathan Lawrentschuk, Louise Emmett, Declan G. Murphy, Michael S. Hofman, Marlon Perera · 2025 · British Journal of Urology
67. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions
    Christian Bernreuther, Ferdous Daghigh, Katharina Möller, Claudia Hube‐Magg, Maximilian Lennartz, Florian Lutz, Sebastian Dwertmann Rico, Christoph Fraune, David Dum, Andreas M. Luebke et al. · 2020 · Pathology & Oncology Research
68. Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization
    So Won Oh, Minseok Suh, Gi Jeong Cheon · 2022 · Nuclear Medicine and Molecular Imaging
69. Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
    Philipp Moritz Adrian Waibel, Ievgen Glavynskyi, Tobias Fechter, Michael D. Mix, Felix Kind, August Sigle, Cordula Annette Jilg, Christian Gratzke, Martin Werner, Oliver Schilling et al. · 2025 · European Journal of Nuclear Medicine and Molecular Imaging
70. Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy
    Darren M.C. Poon, William S. K. Cheung, Peter Ka‐Fung Chiu, Daniel H. S. Chung, John B. T. Kung, Daisy C. M. Lam, Angus Kwong‐Chuen Leung, Anthony C. F. Ng, Joe M. O’Sullivan, Jeremy Yuen‐Chun Teoh et al. · 2025 · Frontiers in Oncology
71. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor
    Kenji Kuroda, He Liu · 2019 · International Journal of Oncology
72. The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations
    Margaret Mary Mansbridge, Eric Chung, Handoo Rhee · 2019 · Medical Sciences
73. Combination of MRI prostate and 18F‐DCFPyl PSMA PET / CT detects all clinically significant prostate cancers in treatment‐naive patients: An international multicentre retrospective study
    Nishanthinie Parathithasan, Elisa Perry, Kim Taubman, Justin Hegarty, Arpit Talwar, Lih‐Ming Wong, Tom Sutherland · 2022 · Journal of Medical Imaging and Radiation Oncology
74. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers
    Katharina Möller, Anna Lena Wecker, Doris Höflmayer, Christoph Fraune, Georgia Makrypidi‐Fraune, Claudia Hube‐Magg, Martina Kluth, Stefan A. Steurer, Till Sebastian Clauditz, Waldemar Wilczak et al. · 2020 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
75. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence
    Simon Kind, Martina Kluth, Claudia Hube‐Magg, Katharina Möller, Georgia Makrypidi‐Fraune, Florian Lutz, Maximilian Lennartz, Sebastian Dwertmann Rico, Thorsten Schlomm, Hans Heinzer A et al. · 2020 · BioMed Research International
76. Recent advances in the targeted fluorescent probes for the detection of metastatic bone cancer
    Peng Wu, Daniel J. Siegwart, Hu Xiong · 2021 · Science China Chemistry
77. Saccharomyces cerevisiae–like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion–positive and fusion-negative cancers
    Christoph M. Burdelski, Ysé Barreau, Ronald Simon, Claudia Hube‐Magg, Sarah Jane Pauline Minner, Christina Koop, Markus Graefen, Hans Heinzer A, Guido Sauter, Corinna Wittmer et al. · 2014 · Human Pathology
78. Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
    Xing Zhou, Xiao Jiang, Luzhou Liu, Xiaoxiong Wang, Chuan Li, Yutang Yao, Ying Kou, Jiaqi Shen, Taipeng Shen, Zeng Li et al. · 2021 · Translational Oncology
79. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
    Christoph M. Burdelski, Laura Borcherding, Martina Kluth, Claudia Hube‐Magg, Nathaniel Melling, Ronald Simon, Christina Möller‐Koop, Philipp Weigand, Sarah Jane Pauline Minner, Alexander Haese et al. · 2017 · Oncotarget
80. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience
    Berna Okudan, Nazim Coskun, Bedri Seven, Merve Ağcıoğlu Atalay, Aslihan Mete Yildirim, Fatma Arzu Görtan · 2021 · Nuclear Medicine Communications
81. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer
    Katharina Grupp, Daniel Ospina-Klinck, Maria Christina Tsourlakis, Christina Koop, Waldemar Wilczak, Meike Adam, Ronald Simon, Guido Sauter, Jakob Robert Izbicki, Markus Graefen et al. · 2014 · The Prostate
82. High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy
    Maria Tsourlakis, Elena Walter, Alexander Quaas, Markus Graefen, Hartwig Huland, Ronald Simon, Guido Sauter, Stefan A. Steurer, Thorsten Schlomm, Sarah Jane Pauline Minner · 2013 · Prostate Cancer and Prostatic Diseases
83. Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
    Mohammad Mohammadzadeh, Masoud Shirmohammadi, Morteza Ghojazadeh, Leila Nikniaz, Mortaza Raeisi, Seyed Ali Mousavi‐Aghdas · 2018 · Prostate International
84. Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients
    Habibollah Dadgar, Manouchehr Seyedi Vafaee, Nasim Norouzbeigi, Esmail Jafari, Ali Gholamrezanezhad, Majid Assadi · 2021 · Urologia Journal
85. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
    Sue‐Jane Wang, Anthony F. Fotenos, Shane C. Masters, Louis Marzella · 2022 · Theranostics
86. Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach
    Nobuki Kazuta, Kazuma Nakashima, Yuta Tarumizu, Takumi Sato, Yoshifumi Maya, Hiroyuki Watanabe, Masahiro Ono · 2024 · Molecular Pharmaceutics
87. Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers
    Mueller Andreas, Ali Attarchi Tehrani, Meiners Jan, Claudia Hube‐Magg, S. Lang Dagmar, Martina Kluth, Christina Tsourlakis Maria, Minner Sarah, Ronald Simon, Guido Sauter et al. · 2019 · Cancer Biology and Medicine
88. Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men
    Naveen Kachroo, Anne Yvonne Warren, Vincent J. Gnanapragasam · 2014 · BMC Cancer
89. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC
    Chandrasekhar Bal, Madhav Prasad Yadav, Sanjana Ballal · 2016 · Clinical Nuclear Medicine
90. Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard
    Eivor Hernes, Mona-Elisabeth R. Revheim, Knut Håkon Hole, Andreas Julius Tulipan, Hilde Strømme, Wolfgang A. Lilleby, Therese Seierstad · 2021 · PET Clinics
91. Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study
    Tomoaki Otani, Tsuneo Saga, Takayoshi Ishimori, Eitaro Kidera, Yoichi Shimizu, Rihito Aizawa, Kiyonao Nakamura, Takayuki Goto, Shusuke Akamatsu, Takashi Mizowaki et al. · 2022 · Annals of Nuclear Medicine
92. Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer
    David R. Cardoza-Ochoa, César Cristancho-Rojas, David J. Pérez, Paola Moreno-Izaguirre, Melissa Guzman, María Cristina Gutiérrez-Rivera, Aarón Patricio Gaxiola Mascareño, Miguel A. Ávila‐Rodríguez, Belén Rivera-Bravo · 2021 · Nuclear Medicine Communications
93. Co-delivery of Siape1 and Melatonin by 125I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer
    Ying Liu, Lin Hao, Yang Dong, Bingzheng Dong, Xinlei Wang, Xing Liu, Zheng-Xiang Hu, Gaochuan Fang, Guang-Yue Wang, Jiaxin Qin et al. · 2023 · Recent Patents on Anti-Cancer Drug Discovery
94. Diagnostic accuracy of bone scan at different PSA levels in biochemical recurrence of prostate cancer
    Karan Bir Singh, Kevin London, Veronica Chi Ken Wong, Robert Mansberg · 2024 · Journal of medical imaging and radiation sciences
95. Comparison of Regularized Reconstruction and Ordered Subset Expectation Maximization Reconstruction in the Diagnostics of Prostate Cancer Using Digital Time-of-Flight 68Ga-PSMA-11 PET/CT Imaging
    Olof Jonmarker, Rimma Axelsson, Ted Nilsson, Stefan Gabrielson · 2021 · Diagnostics
96. Prognostische und prädiktive molekulare Marker urologischer Tumoren
    Arndt Hartmann, Thorsten Schlomm, Simone Bertz, Joana Heinzelmann, Sebastian Hölters, Ronald Simon, Robert Stoehr, Kerstin Junker · 2014 · Der Urologe
97. Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review
    Angela Y. Jia, Rojano Kashani, Nicholas George Zaorsky, Brian Christopher Baumann, Jeff M. Michalski, Jacqueline Esthappan Zoberi, Ana P. Kiess, Daniel Eidelberg Spratt · 2022 · Practical Radiation Oncology
98. PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
    Vinh Ngoc Bui, Lena Maria Unterrainer, Matthias Brendel, Sophie Carina Kunte, Adrien Holzgreve, F. Allmendinger, Peter Bartenstein, Frederick Klauschen, Marcus Unterrainer, Michael D. Staehler et al. · 2023 · Biomedicines
99. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer
    Sören Alexander Weidemann, Charlotte Sauer, Andreas M. Luebke, Christina Möller‐Koop, Stefan A. Steurer, Claudia Hube‐Magg, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Till Sebastian Clauditz et al. · 2019 · BMC Cancer
100. PSMA hybrid imaging in prostate cancer – current applications and perspectives
     Daniel Koehler, Christoph Berliner, Farzad Shenas, Amir Karimzadeh, Ivayla Ilieva Apostolova, Susanne Klutmann, Gerhard Adam, Markus Sauer · 2023 · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren